Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
262 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00701766 | BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia | completed | Phase 2 | 71 | Boehringer IngelheimINDUSTRY | 2 | May 16, 2014 | clinicaltrials |
| NCT00706498 | Phase II Study of BI 2536 in Prostate Cancer | completed | Phase 2 | 20 | Boehringer IngelheimINDUSTRY | 1 | May 16, 2014 | clinicaltrials |
| Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients |
| completed |
| Phase 2 |
| 41 |
| Boehringer IngelheimINDUSTRY |
| 2 |
| Mar 26, 2014 |
| clinicaltrials |
| NCT00425854 | An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer | completed | Phase 2 | 50 | Boehringer IngelheimINDUSTRY | 2 | Dec 31, 2013 | clinicaltrials |
| NCT00826267 | 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab | completed | Phase 2 | 29 | Boehringer IngelheimINDUSTRY | 4 | Dec 31, 2013 | clinicaltrials |
| NCT01003899 | A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR] | completed | Phase 2 | 43 | Boehringer IngelheimINDUSTRY | 1 | Dec 31, 2013 | clinicaltrials |
| NCT00708214 | BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer | completed | Phase 2 | 28 | Boehringer IngelheimINDUSTRY | 1 | Dec 30, 2013 | clinicaltrials |
| NCT00875433 | Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours | completed | Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 1 | Dec 30, 2013 | clinicaltrials |
| NCT00756223 | Phase I Study of BI 831266 in Patients With Advanced Solid Tumours | completed | Phase 1 | 25 | Boehringer IngelheimINDUSTRY | 1 | Nov 21, 2013 | clinicaltrials |
| NCT01951846 | To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours | completed | Phase 1 | 61 | Boehringer IngelheimINDUSTRY | 1 | Sep 27, 2013 | clinicaltrials |
| NCT00003328 | Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer | completed | Phase 3 | 600 | Boehringer IngelheimINDUSTRY | 1 | May 21, 2010 | clinicaltrials |
| NCT00730821 | Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors | completed | Phase 1 | 28 | Boehringer IngelheimINDUSTRY | 1 | Aug 21, 2009 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials